Ka noqoshada da'da: cilmiga
Badanaa cudurrada oo nolosheena dhamaystiraan waxaa ka mid ah sababo kala duwan: da'da. Markii ugu horeysay, cilmi-baadhayaashu waxay ku adkaan kartaa xayawaanka iyo qaar ka mid ah astaamaheeda ee unugyada. Waxba kama jiraan ayaa weli la xaqiijiyay in lagu beddelo da'da aadanaha, laakiin saynisku waa run, waana dhaqdhaqaaq degdeg ah.
Snuupo / Wikimedia Commons (CC BY-SA 4.0)
Inta badan taariikhda, dadka dhintay yar oo cudurrada faafa, dhaawacyo iyo uurka. Maanta, in badan oo ka mid ah dunida, waxay dhintaan da’da, iyo ay dhintaan oo ka mid ah liiska gaaban ee cudurrada joogtada ah: xanuunka wadnaha, stroke, kansarka, dementia, sonkorowga iyo cudurka wadnaha. Mid kasta oo ka mid ah cudurradaas waxay leedahay xirfadlayaalkeeda, deeqaha iyo daawooyinka. Laakiin waxay wadaagaan mid ka mid ah sababaha khatarta ah ee ugu weyn, oo ma aha sigaar cabista, cunto ama jeermis. Waa da’da. A sii kordhaya qaybta cilmiga, la yiraahdo geroscience, weydiinaya su’aal fudud: ka dib markii dagaalka ka dhan ah cudur kasta oo da’da kala duwan, ma waxaan hoos u dhici kartaa habka da’da ee ay ku socdaan oo dhan? Boggan wuxuu qeexayaa, sida cad iyo run ahaantii sida aan awoodno, waxa cilmi baaristaas muujisay, waxa ay ma aha, iyo waxa ay ka dhigan tahay in dhammaanteen.
Maxaa da’da ah waa aasaaska ugu badan ee cudurka joogtada ah
Fiiri in ay tahay in ka badan oo dhan cudurka caadiga ah ee joogtada ah by da’da iyo qaabka la midka ah ayaa soo muuqan: yar yar dadka waaweyn ee dhalinyarada, markaas kor u kacday si tartiib ah oo toban sano kasta. Dalka Maraykanka ee 2025, ku saabsan 0.5 boqolkiiba dadka waaweyn da’doodu u dhaxayso 18 ilaa 44 ayaa marnaba la aqoonsaday cudurka wadnaha; dadka da’doodu u dhexeyso 75 iyo ka badan waxaa jiray 19 boqolkiiba. Wax kasta oo kansarka: 2 boqolkiiba ka dhanka ah 33 boqolkiiba. Arthritis: 6 boqolkiiba ka dhanka ah 53 boqolkiiba (NCHS, NHIS 2025). Dib u eegis cusub kansarka kor u kacaya oo ku saabsan 236 per 100,000 qof sanadkii da’doodu tahay 40 ilaa 44 in ku saabsan 2,400 at 80 ilaa 84 (NCI SEER). Qaybta dadka ku nool cudurka maskaxda ayaa si toos ah u laba-laabma shan ilaa lix sano gudahood ka dib 65, oo gaaraya hal saddex meelood meel 90 iyo in ka badan (Manly et al., 2022).
In xogta Mareykanka kor ku xusan, cudurka wadnaha waa ku saabsan 38 jeer sida caadiga ah ee 75 iyo ka badan sida ay tahay 18 ilaa 44. Sidaas darteed, koox cilmi-baarisayaasha ugu caansan ayaa lagu sheegay in da’da “waxay tahay sababta khatarta ugu weyn ee dadka badankoodu ay qabaan cudurrada joogtada ah” iyo inay da’da la tacaali karaan oo keliya waxay dib u dhigi kartaa qaar ka mid ah (Kennedy et al., 2014). Tani waa geroscience qiyaasta. Waxay leedahay natiijo dhab ah. Daawaynta cudurka da’da ayaa ku dareysa nolosha oo aad u yar, maxaa yeelay kuwa kale waxay sugayaan: dadka laga badbaadiyay weerarka qalbiga waxay wajahaan kansarka, dementia ama xanuun qaar ka mid ah sano ka dib. Ka yaraynta da’da waxay ka dhigi doontaa inay dib ugu soo noqdaan isla markiiba.
Waxgaradka dhaqaalaha waxay isku dayeen inay ku dhejiyaan qiimaha ah ee arrintan. A 2013 cilmi baarista ee Mareykanka waxaa la helay in dib u dhac yar oo ku saabsan da’da ah ayaa lagu dari doonaa 2.2 sano oo nolosha la filayo, kuwa badankoodu caafimaad qabaan, qiimaha ku saabsan $ 7.1 trillion ka badan 50 sano (Goldman et al., 2013). Cilmi-baaris 2021 ayaa lagu qiyaasay in yareynta da’da oo ku filan si loo kordhiyo hal sano oo nolosha la filayo ay qiimo u leedahay $38 trillion to the US, and ten years $367 trillion (Scott, Ellison iyo Sinclair, 2021). Kuwaas waa qaabab ku dhisan ee qiyaasaha, laakiin waxay muujiyaan sababta xukuumadaha iyo maal-gashiga ay tixgelin.
Maxaa dhab ahaantii u xun: astaamaha da’da
Da’da ma aha hab kaliya laakiin in badan, oo ka dhaca isla markaana isku darsadaan. Sanadkii 2013, koox uu hoggaaminayo Carlos López-Otín ayaa ku ururisay sagaal markhaatiyo da’da, sanadkii 2023na waxay liiska u kordhiyeen laba iyo toban (López-Otín et al., 2013; López-Otín et al., 2023). In hadalka cad:
- Genomic isbeddelka: dhaawaca DNA dhistaa ka dhaqso badan in ay la dayactiro.
- Telomere attrition: daboolka ilaaliyaha ee dhamaadka kromosomes-ka ayaa hoos u dhacaya.
- Epigenetic isbedelada: calaamadaha kiimikada in ay gene on iyo off ka soo wareegto qaabkooda dhalinyarada ah.
- Ilaalinta proteostasis: Phosphatidylserine (PS) waa enzyme muhiim u ah in ay ka hortagaan cudurka.
- Macroautophagy la’aan: nidaamka dib u soo kabashada ee unugyada ayaa hoos u dhacay.
- Deregulated cunto-qaadashada dareenka: calaamadaha koritaanka sida mTOR iyo insulin joogaan ku xiran marka dayactirka ka wanaagsan yahay.
- Mitochondrial dysfunction: xarumaha tamarta ee unugyada waxay sameeyaan wax yar oo tamarta ah iyo waxyaabo kale oo waxyeello badan leh.
- Cellular senescence: unugyada dhaawacmay joojiyaan qaybinta laakiin diido inay dhintaan, iyo sii daayo calaamadaha inflammation.
- Stem cell exhaustion: kaydka oo dayactira timaha hoos u dhaca.
- Xeerka isgaarsiinta intercellular: calaamadaha u dhexeeya unugyada iyo xubnihii ku sifoobi.
- Crohn inflammation: hoos u, joogto ah inflammation, qaar ka mid ah waxaa loo yaqaan “inflammageing”.
- Dysbiosis: miisaanka microbes ee wareegyada caloosha.
Qof kasta oo qaabka on page this ujeedada mid ama in ka badan oo ka mid ah astaamahaan. Tilmaamaha u ah calaamad waa in ay adag tahay: waa in uu la yimaado da’da, ka dibna si degdeg ah u kor loo qaado waa in ay sii socdaan oo ku saabsan da’da, iyo ka dibna si degdeg ah u hoos u dhac ah waa in ay sii socdaan oo ku saabsan da’da. Imtixaankan ugu dambeeyay waa meesha rajada ka timaado, sababtoo ah qaar ka mid ah hababkaas, cilmi-baarayaasha horeyba u sameeyeen xayawaanka.
Sideen u hubanti nahay? Miisaanka caddayn
Erayga “anti-aging” waxaa ka mid ah wax kasta oo laga bilaabo dhaqanka la xaqiijiyay in malaayiin qof si ay fikradaha lagu tijaabiyay daraasad mouse kaliya. Si ay u kala fogaadaan, hab kasta oo ku saabsan bogga this qaado mid ka mid ah afar heerar:
- Waxay dadka ku caddahay: cilmi-baaris weyn oo aadanaha ah iyo tijaabooyin isku dhafan ayaa muujinaya in cudurro iyo dhimasho yar yihiin.
- Baadhitaanno dadka u ballan qaaday: baaritaanno randomised in dadka muujiyaan saameynta dhabta ah, laakiin weli ma ku da’da oo keliya.
- Xoog leh ee xayawaanka : la soo celiyo, natiijooyinka xoog leh ee xayawaanka; caddayn aadanaha yar, isku dar ah ama kaliya bilaabay.
- Hore ama speculative: daciif ah, muransan ama caddayn hal-barashada, ama tijaabooyinka aadanaha ilaa hadda inta badan aan faa’iido cad.
Si ay u fudud: nothing on this page ayaa weli la muujiyay in ay yaraato ama ka soo horjeeda da’da aadanaha oo dhan. No dawada, dheeraadka ah ama daaweynta jeermis waa la ansixiyay si loo daaweeyo da’da meel kasta oo dunida. Sidaas maxay yihiin cilmi-baadhayaal muhiim ah ku faraxsan? Sababtoo ah labaatan sano ka hor qofna ma awoodi karo inuu si kalsooni leh u kordhiyo nolosha xayawaanka caadiga ah ee daawada, iyo hadda daawooyinka badan ayaa sameeya, imtixaanno taxaddar leh oo laga sameeyo labaratooro kala duwan isla markiiba; sababtoo ah unugyada hore waxaa loo sameyn karaa inay ku dhaqmaan sida kuwa yaryar oo kale oo ku jira digir iyo, qaar ka mid ah timaha, xayawaannada nool; iyo sababtoo ah baaritaanka bini’aadamka ee ugu horreeyay ee loogu talagalay biolojiga da’da, inkasta oo aan ahayn cudur keliya, hadda waa socdaan. Jaadka ka mid ah mouse in aadanaha waa dheer, iyo fikrado badan oo ballaaran ku fashilmaan on it. Laakiin jidka waa cad yahay.
Cunto-qaadashada: mTOR iyo rapamycin
Xaqiiqada heerka: ballanqaad tijaabooyinka aadanaha
Waa maxay. Cell kasta oo ay go’aan ka gaarto haddii ay koraan ama in ay dayactirka. A protein complex la yiraahdo mTOR (targetka mechanistic of rapamycin) sameeyaan in wicitaan: marka cuntada iyo calaamadaha koritaanka waa tiro badan, mTOR wuxuu leeyahay “u koraan”; marka ay yar yihiin, waxay tallaabooyin dib u celiyaan oo ka mid ah qaybaha uu ku wareegsan yahay dayactirka, oo ay ku jiraan dib u soo kabashada qaybaha loo isticmaalo-out autophagy. Nolosha dadka waaweyn oo dhan, mTOR u muuqdaan in ay sii joogi on ka badan waa wanaagsan naloo. Ka dhigi hoos waa mid ka mid ah hababka ugu sii socon in ay nolosha dheereeyaan ee cayayaanka, digaaga, dhirta iyo fircoon.
Rapamycin waa daawo ka hortagta mTOR. Waxaa la ogaaday in tusaale ah ciidda ka Rapa Nui (Isle Easter), taas oo ay bixisay magaceeda, halkaas oo uu ku sameeyey bakteeriyada, * Streptomyces hygroscopicus * (Vézina, Kudelski iyo Sehgal, 1975). In daawooyinka sare waxaa la isticmaalay muddo sano ah si ay u joojiyaan jirka diidmada organs transplanted.

In xayawaanka. In 2009 US National Institute on Aging’s Interventions Testing Program, oo tijaabiyey isku-dhafka ee faraska genetically kala duwan saddex labbo labo jeer, waxay sheegeen in rapamycin nolosha dheereeyay xitaa marka ay markii ugu horeysay la siiyay at 600 maalmood jir ah, dib u dhacay nolosha farta. Tan iyo da’daas, nolosha la filayo kor u kacay 28 boqolkiiba ragga iyo 38 boqolkiiba dumarka (Harrison et al., 2009). Marka daawo sare oo la bilaabay da’da dhexe, nolosha dhexdhexaad ah kor u kacay 23 boqolkiiba ragga iyo 26 boqolkiiba dumarka (Miller et al., 2014). Rapamycin waa daawo kaliya oo keliya ee barnaamijka si ay u shaqeeyaan si xoog leh labada jinsi, iyo waxaa weli ah daawo nolosha ugu badan ee soo noqnoqda ee duurjoogta.
In dadka. Xujada aadanaha waa yar laakiin run ah. In tijaabo randomized in dadka qaangaarka ah, lix toddobaad ee everolimus, qaraabadiisa dhow oo rapamycin, hagaajin jawaabta si ay u tallaalka cudurka faafa by ku saabsan 20 boqolkiiba (Mannick et al., 2014), iyo tijaabo ka dib oo isku dar ah la xiriira hoos u cudurrada sanadka soo socda (Mannick et al., 2018). Laakiin tijaabo faashad 3 ah oo ka weyn daawo la mid ah, in ka badan 1,000 dadka waaweyn, ma helin hoos u dhac ku yimaada cudurka neefsashada (Mannick et al., 2021). Daraasad PEARL siiyey dadka waaweyn ee caafimaad qaba daawooyinka toddobaadle ah oo hooseeya rapamycin 48 todobaad. Waxayna ma beddelin miisaankeeda ugu weyn, visceral dufanka, iyo saameynta kale ee la mid ah sida placebo; qaar ka mid ah tallaabooyinka labaad, sida muruqyada dufanka leh ee haweenka ku jira daaweynta sare, ayaa kor u kacay (Moel et al., 2025). A 2024 dib u eegista 19 daraasado ma helin wax dhacdooyin xun oo daran dadka caafimaad qaba, laakiin cudurro badan iyo dhiigga sare ee dhiigga dadka horeyba u lahaa cudurka da’da (Lee, Kuerec iyo Maier, 2024).
Risks. At daawooyinka transplantation, rapamycin hoos u nidaamka difaaca jirka iyo qaado digniin ku saabsan cudurrada daran iyo qaar ka mid ah kansarka. Afka ulcers, sare kolesterol iyo triglycerides, yara dhaawici jiritaanka iyo biyaha dhismaha-up waa dhammaan saameynta kale ee liiska (US FDA sirolimus label). In faraska, isticmaalka dheer ee sidoo kale sababi kara diidmada insulin (Lamming et al., 2012). Cilmi-baarayaasha hadda baaritaan ku yar iyo daawooyinka kala go’an, iyo daawo cusub oo kaliya ka hortagga qaybta mTOR la xiriira nolosha dheer.
Senolytics: ka saar “zombi” unugyada
Xaqiiqda heerka: xoog leh ee xayawaanka
Waa maxay. Markay xayawaanku aad u dhaawacmo, waxay gali kartaa xaalad la yiraahdo senescence: waxay joojisaa kala qaybinta, taas oo ka ilaalisa kansarka, laakiin ma dhimanayso. Senecious cells dhisaan la da’da. Ka sii xumaan, waxay soo saaraan cocktail of calaamadaha inflammation, senescence-la xiriira secretory phenotype (SASP), in ay waxyeello u keento unugyada caafimaad qaba oo ku hareeraysan (Coppé et al., 2008). Senolytics waa daawooyinka loogu talagalay in la dilo unugyada senescent doorasho.

In xayawaanka. In 2011, cilmi-baarayaasha genetically fardaha injineernimada si ay u cellhooda senescent la saari karo baahida. Ka saarkooda dib u dhacay dhaawaca da’da ku saabsan dufanka, muruqyada iyo indhaha (Baker et al., 2011). In fircoon caadi ah, ka saaro unugyadaas da’da dhexe ee dheereeyay nolosha dhexdhexaadka ah by 24 ilaa 27 boqolkiiba (Baker et al., 2016). Isku-darka daawada senolytic ee ugu horreeyay, dasatinib plus quercetin, waxaa la helay 2015 (Zhu et al., 2015). La siiyay firir aad u da’da weyn, waxay hagaajineysaa shaqada jirka iyo kordhinta nolosha oo ku hadhay 36 boqolkiiba (Xu et al., 2018). Fisetin, isku dar dabiici ah oo laga helay strawberries, nolol dheer marka la siiyo firir hore (Yousefzadeh et al., 2018).
In dadka. Natiijada ugu horeysay ee aadanaha waa yar yihiin oo isku darsan. In 14 dadka qaba cudurka wadnaha, idiopathic fibrosis wadnaha, saddex toddobaad oo dasatinib iyo quercetin kor u socday fogaanshaha iyo xawaaraha, in kasta oo aan shaqada wadnaha, in baaritaan aan koox placebo (Justice et al., 2019). Saddex qof oo qaba cudurka wadnaha ee sonkorowga, daawooyinka ayaa hoos u dhigay unugyada senescential ee dufanka iyo maqaarka iyo hoos u dhigida calaamadaha xanuunka dhiigga (Hickson et al., 2019). Laakiin baaritaan randomized in 60 haweenka ka weyn, daawooyinka ma hagaajin lafaha guud ahaan; kaliya dumarka leh unugyada ugu senescent u muuqday inay faa’iido (Farr et al., 2024). In daraasad suurtogalnimada shan qof oo qaba cudurka Alzheimers, dasatinib gaadhay biyo ku wareegsan maskaxda laakiin quercetin ma (Gonzales et al., 2023). Fisetin tijaabooyin weyn ee Klinikka Mayo weli socdaan (ClinicalTrials.gov NCT03675724).
Shirkadda ugu horeysay ee senolytics ku dhisan, Unity Biotechnology, tijaabisay injiin indhaha, UBX1325 (foselutoclax), si ay u cudurka indhaha diabetic. Ka dib markii baaritaan hore oo dhiirigelin, ka weyn 2-aad ee tijaabada la barbardhigo daaweynta caadiga ah ku fashilmeen ujeedka ugu weyn (Unity Biotechnology, 2025), iyo shirkadda waxaa la burburiyey ka dib sanadkii (SEC gudbinta, 2025).
Risques. Dasatinib waa daawo kansarka leh saameynta kale ee daran, oo ay ku jiraan saameynta tirada dhiigga. Senecious cells sidoo kale waxay leeyihiin shaqooyin faa’iido leh, tusaale ahaan, in daawo jeermis, sidaas darteed iyaga ka saar ma aha khatar la’aan.
NAD +, NMN iyo NR
Xujaynta heerka: hore ama speculative
Waa maxay. NAD + waa molecule yar oo ka mid ah unug kasta oo u baahan in ay cunto ku beddelaan tamarta iyo dayactirka DNA. heerarka hoos u dhaca da’da timaha qaar. Labada hordhac ah ee jirka uu ku noqon karo NAD +, nicotinamide mononucleotide (NMN) iyo nicotinamide riboside (NR), waxaa loo iibiyaa sida daawooyinka.
Xaraashka. Fiidyaha, sanadka NMN ee biyaha cabitaanka ayaa fududeeyay isbeddello badan oo la xiriira da’da, oo ay ku jiraan miisaan kordhinta iyo isticmaalka tamarta hoos u dhaca (Mills et al., 2016), iyo NR waxay hagaajisay shaqada mitochondrial iyo unugyada asalka ah iyo nolosha aad u dheerayd ee fidiyaha hore (Zhang et al., 2016). Laakiin marka barnaamijka imtixaannada dhexdhexaadinta uu tijaabiyay NR qaabkeeda adag, ma uusan kordhin nolosha labada jinsi (Harrison et al., 2021).
Dadku. NR iyo NMN waxay si kalsooni leh u kordhiyaan NAD + dhiigga (Martens et al., 2018). Tijaabada wanaagsan ee ugu caansan ayaa NMN u siisay 25 haween ah oo qaba cudurka sonkorowga toban todobaad: dareen-celinta insuliinka muruqyada ayaa kor u kacay ilaa boqolkiiba 25, halka cadaadiska dhiigga, dufanka dhiigga iyo isku-dhafka jirka aysan isbeddelin (Yoshino et al., 2021). In trial yar ee cudurka Parkinson, NR kor u NAD maskaxda leh hagaajinta caafimaad oo fudud (Brakedal et al., 2022); baaritaan weyn ayaa dhammaaday iyo natiijada la sugayo. Tijaabooyinka in ay isku darsadaan tijaabooyinka ilaa hadda ka heli kartaa dheeraadka ah ee ammaan ah oo ku saabsan muddada gaaban laakiin inta badan aan faa’iido cad u siin sonkorta dhiigga, dufanka dhiigga ama muruqyada (Zhang et al., 2025; Prokopidis et al., 2025). Maxaa aan la muujin: in kor u qaadista NAD + ka yaraato da’da ama ka hortagtaa cudur kasta oo dadka ku dhaca.
Qaanuun. 2022, Maamulka Cuntada iyo Daawooyinka Mareykanka wuxuu sheegay in NMN aan loo iibsan karin sida daroogada cuntada sababtoo ah waxaa lagu bartey daawo; Sebtember 2025 waxay dib u dhigtay aragtidaas (FDA, 2025). In la iibiyo waxba kama sheego haddii ay tahay in uu shaqeeyo.
Sirtuins iyo sheekada resveratrol
Xujaynta heerka: hore ama speculative
Waa maxay. Sirtuins waa qoyska enzymes, toddoba ka mid ah lo’da, oo isticmaala NAD + si ay u xakameeyaan dayactirka DNA, metabolism iyo hawlgalka jeermiska. In 2003 daraasad lagu sheegay in resveratrol, isku darka laga helay canabka cad, hawlgeliyay sirtuin iyo dheereeyay nolosha xamiiska (Howitz et al., 2003). In 2006 resveratrol hagaajiyey caafimaadka iyo nolol maalmeedka ee firir ku saabsan cunto sare-calorie (Baur et al., 2006). In 2008 shirkadda daawada GSK iibsaday Sirtris, shirkad horumarinta sirtuin activators, oo ku saabsan $ 720 milyan (GSK iyo Sirtris, 2008).
Maxaa ka faded. Sheekada ma haysto si fiican. Resveratrol ma kordhin nolosha firir caadi ah oo ku saabsan cunto caadi ah (Pearson et al., 2008), oo ay ku jiraan barnaamijyada Interventions Imtixaan (Miller et al., 2011). Biochemists helay in ay muujisay hawlgelinta sirtuin SIRT1 ku xiran tahay tag fluorescent artificial loo isticmaalo imtixaanka (Kaeberlein et al., 2005; Pacholec et al., 2010). Iyo saameynta nolosha asalka ah ee sirtuin dheeraad ah oo ku jira digaaga iyo shimbiraha si weyn u dhintay marka backgrounds genetic ahaa si sax ah loo maamulo (Burnett et al., 2011).
Waa maxay weli la aamini karo. Sirtuins weli muhiim u ah. Fiirso injineernimada si ay u sameeyaan in ka badan oo ka mid ah sirtuin, SIRT6, noolaa muddo dheer: ragga kaliya ee daraasadda koowaad (Kanfi et al., 2012), iyo daraasad dambe 27 boqolkiiba nolosha dhexdhexaadka ah ee ragga iyo 15 boqolkiiba dumarka, la yar yahay daciifnimo (Roichman et al., 2021). Taasi waa genetics, ma pil. No sirtuin-activating dheeraad ah ayaa la muujiyay in ay yaraadaan da’da dadka.
Telomeres iyo telomerase
Xujaynta heerka: hore ama speculative
Waa maxay. Telomeres waa isku-dhafka DNA ee ku soo noqnoqda oo ka buuxa dhamaadka kromosomesyadayaga, sida tilmaamaha plastikka ah ee boorsada. Waxay yareeyaan wax yar markasta oo unugyada badankoodu kala qaybsamaan; marka ay noqdaan kuwo aad u gaaban, unuggu wuu joojiyaa inuu kala qaybsamo ama wuu dhimanayaa. Enzyme la yiraahdo telomerase waxay dib u dhisi karaan. Elizabeth Blackburn, Carol Greider iyo Jack Szostak waxay qaybsadeen abaalmarinta Nobel ee 2009 ee Fisiolojiga ama Daaweynta si ay u ogaadaan sida tani u shaqeyso (Nobel Prize, 2009).

In xayawaanka. In 2012 koox ka tirsan Xarunta Cilmi baarista Kansarka ee Qaranka Spain siiyey firirro waaweyn daaweynta jeermiska oo dib u dhigay telomerase. Nolosha dhexdhexaad ah ayaa kor u kacay 24 boqolkiiba ee fidrada lagu daweeyo hal sano jir iyo 13 boqolkiiba ee fidrada lagu daweeyo laba sano, iyadoo aan kordhin in kansarka (Bernardes de Ciise et al., 2012). Waxay sii ahaan doontaa natiijo muhiim ah laakiin si weyn looma soo celin.
The dhibaatada kansarka. Cells Cancer u baahan yihiin in ay qaybiyaan aan xad lahayn, iyo kuwa badan oo ka mid ah waxay sameeyaan iyada oo loo marayo isku-beddelka telomerase on: in cilmi baaris taariikhi ah, 90 of 101 timaha tusaalooyin ahaa hawlgalka telomerase, iyo midna ka mid ah 50 timaha caadiga ah ma (Kim et al., 1994). Dadka kuwaas oo jeermisyada siiyaan iyaga telomeres dheer leeyihiin khatar ka yar ee cudurrada wadnaha laakiin khatarta sare ee kansarka badan, oo ay ku jiraan glioma, adenocarcinoma iyo melanoma (Haycock et al., 2017). Telomeres gaaban ma aha oo kaliya “xun” iyo kuwa dheer “fiican”.
In dadka. Qaar ka mid ah cudurrada da’da yar ee la dhaxlo, sida dyskeratosis congenita, waxaa sabab u ah telomerase qalad iyo sababta oo ah fashilka timaha, xanuunka wadnaha iyo dhimashada hore (Armanios iyo Blackburn, 2012). In baaritaan ku dhacay bukaannada, hormoonka danazol telomeres dheereeyay 11 ka mid ah 12 qof oo la qiimeyn karo (Townsley et al., 2016). Taasi waa daaweynta cudur aad u yar, ma aha in ay da’da. Laa yaab ee wax kasta oo sheegasho ah in alaabta ama isbitaal “u dheereeyaa telomeres aad” si aad u yaraan: in 2015 madaxa shirkadda mid ka mid ah ayaa sheegay inay heshay daawo telomerase jeermiska aan la caddayn dibadda, laakiin dacwadaha weligood looma aqoonsan yahay oo ku saabsan daraasadda isku-eegista (MIT Technology Review, 2015).
Qaybta reprogramming la faahfaahinta Yamanaka
caddayn heerka: xoog leh ee xayawaanka, tijaabada ugu horeysay ee aadanaha socda
Waa maxay. In 2006 Shinya Yamanaka muujiyay in ay ku wareegaan oo kaliya afar jeer, hadda loo yaqaano Yamanaka sababaha (OCT4, SOX2, KLF4 iyo c-MYC, ama OSKM), ka dhigi kartaa mid ka mid ah unugyada maqaarka ee da’da weyn dib u celis ah oo ku jira unugyo sida oo kale oo ay noqon karaan nooc kasta oo unugyo ah (Takahashi iyo Yamanaka, 2006). Wuxuu ku qaybsaday abaalmarinta Nobel 2012 (Nobel Prize, 2012). Waddada dheer, da’da unugyada waa la nadiifiyey: calaamadaha kiimikada ee DNA-ga waxay ku noqdaan qaab dhalinyaro ah. Fikradaha parcial reprogramming waa in la beddelo sababaha ku saabsan oo keliya si kooban, muddo dheer oo ku filan si ay u soo celiyaan calaamadaha da’da laakiin aan ku filnayn muddo dheer oo loogu talagalay cell in ay ka fogaadaan waxa uu yahay.

Hawlaha. In 2016, fidrada da’da ka hor ayaa la siiyay OSKM wareegyada, laba maalmood iyo shan maalmood oo ka maqan. Xubnaha ay muujiyeen calaamado yar oo da’da iyo waxay noolaayeen muddo dheer (Ocampo et al., 2016). Sanadkii 2020, saddex ka mid ah faa’iidooyinka (OSK, oo aan la gelin c-MYC-ka kansarka la xiriira) waxaa loo gudbiyay indhaha firirooyinka leh dhaawacyo glaucoma ah iyo firirooyin hore, waxayna dib u soo celiyeen aragtidooda iyagoo dib u dhigay calaamadaha DNA ee unugyada neerfaha (Lu et al., 2020). Reprogramming qayb ka mid ah muddada dheer ee caadiga ah ee firfircoon ee firfircoon ayaa u dhaqaaqay calaamado molecular badan oo ku wajahan dal yar (Browder et al., 2022), iyo daraasad yar, daaweynta jeermiska OSK oo la siiyay firfircoonaanta ragga wayn waxay laba-laabiyeen noloshooda ugu dambeysay (Macip et al., 2024).

Risks. Going aad u fog waa khatar. Marka ay sababaha la wareegay si joogto ah oo ku nool fidrada, unugyada ay aqoontooda ka tageen iyo timaha loo yaqaan teratomas (Abad et al., 2013); in daraasad kale, OSKM sii socday keenay cidhibta iyo cudurka caloosha iyo dhimashada gudahood toddobaad (Parras et al., 2023). Tallaalka, waqtiga iyo noocyada unugyada ee jeermiska helaa ayaa ah caqabadda ugu weyn.
Shirkadaha iyo tijaabada koowaad. Qaybta reprogramming ayaa xiisayn lahaa qaar ka mid ah maalgashiga ugu weyn ee biotechnology. Altos Labs la bilaabay bishii Janaayo 2022 la $3 billion (Altos Labs, 2022). Retro Biosciences, backed with $180 milyan oo Sam Altman (MIT Technology Review, 2023), shaqada on reprogramming iyo wuxuu leeyahay daawada ugu horeysay, tallaalka ujeedada dib u soo kabashada unugyada, galay fasax 1 tijaabo in 2025 (Retro Biosciences, 2026). NewLimit kor u $435 milyan oo 2026 iyo wuxuu leeyahay qorshayaal tijaabada bini’aadamka ugu horeysay ee daaweynta mindhicirka (NewLimit, 2026). Daaweynta reprogramming ugu horeysay si ay dadka u gaarto waa ER-100 ka Life Biosciences, daaweynta jeermiska OSK lagu shubay indhaha laba cudur oo nerve optic, glaucoma iyo aan arteritic anterior ischaemic neuropathy (NAION). US Cuntada iyo dawooyinka Administration saxiixday tijaabada bishii Janaayo 2026 (Life Biosciences, 2026), iyo bukaanka ugu horeeyay waxaa la daawayn doonaa June 2026 in faashad 1 daraasadda amniga 18 qof (ClinicalTrials.gov NCT07290244; Life Biosciences, 2026). Natiijooyinka qaadan doonaan sano.
Wadooyinka kale ee muhiimka ah
Daawooyinka oo kordhiya nolosha mouse
Xaqiiqda heerka: xoog leh ee xayawaanka
Tan iyo 2004 Barnaamijka Iibsiga Interventions ayaa tijaabiyey 54 isku dar ah oo ka badan 30,000 firir (Jiang et al., 2025). Naqshadeynta waa adag tahay: tijaabada la mid ah waxaa lagu fulin doonaa saddex lab, oo leh faraska jeermiska kala duwan, sidaas darteed natiijada waa in ay ku jiraan dhammaantood. In ka badan rapamycin, isku-dhafka qaar ka mid ah ayaa la soo dhaafay: daawada sonkorowga acarbose ku daray 22 boqolkiiba in uu nolol dhaxal ah nin laakiin kaliya 5 boqolkiiba dumarka (Harrison et al., 2014); 17-alpha-estradiol, qaabka hoose ee estrogen, ku daray 19 boqolkiiba ragga iyo waxba dumarka (Strong et al., 2016); iyo daawada sonkorowga canagliflozin ku daray 14 boqolkiiba ragga oo keliya (Miller et al., 2020). Rapamycin oo la isku daray acarbose siiyey guulaha ugu weyn ilaa hadda: 34 boqolkiiba ragga iyo 28 boqolkiiba dumarka (Strong et al., 2022). Maxaa ragga ka faa’iideystaan si aad u badan oo badanaa waa su’aal muhiim ah. Wax ka mid ah daawooyinkan waxaa la tijaabiyay in ay dadka ku dhashaan.

Metformin iyo baaritaanka TAME
Xujaynta heerka: hore ama speculative
Metformin waa daawo cudurka sonkorowga ee la isticmaalo in ka badan lixdan sano. A 2014 cilmi baarista diiwaanada caafimaadka UK helay in dadka qaba cudurka sonkorowga qaadan metformin noolaa wax yar ka badan oo la mid ah dadka aan sonkorowga lahayn (Bannister et al., 2014), taas oo ka dhigaysa murashax hoggaamineed ee daawo anti-da’da. The TAME trial (Targeting Aging with Metformin) waxaa loogu talagalay in lagu tijaabiyo haddii ay dib u dhigeysa cudurka wadnaha, kansarka, dementia iyo dhimashada oo dhan dadka waaweyn ee hore, iyo in la qanciyo maamulayaasha si ay u daaweeyaan da’da sida wax daroogada u diiradda saari kartaa (Barzilai et al., 2016). Sida September 2026 aan ka heli karin natiijooyinka la daabacay. Intaas waxaa sii dheer, kiisku wuxuu yaraa: daraasad Denmark ah oo ay ku jiraan laba-laab ayaa helay faa’iido nolol aan la heli karin dadka isticmaala metformin (Keys et al., 2022); metformin keliya ma kordhin waxtar leh nolosha farta ee Barnaamijka Imtixaannada Dhexdhexaadinta (Strong et al., 2016); iyo laba tijaabo oo dad waaweyn ah ayaa ka faa’iideystay tababarka jimicsiga (Konopka et al., 2019; Walton et al., 2019).
Daawooyinka GLP-1
Xaqiiqada heerka: ballanqaad tijaabooyinka aadanaha
Daawooyinka sida semaglutide ka dhigan hormoonka caloosha, GLP-1, iyo waxaa loo horumariyey si loogu daro sonkorowga iyo miisaanka. Marka la eego tijaabada SELECT ee 17,604 dadka qaba cudurka sonkorowga iyo xanuunka wadnaha, semaglutide wuxuu yareeyay weerarrada wadnaha, dhaawacyada iyo dhimashada wadnaha oo ah 20 boqolkiiba (Lincoff et al., 2023). Cilmi baarista da’da Mareykanka la cudurka sonkorowga ku xiran GLP-1 daroogada in khatarta ah xaaladaha badan, oo ay ku jiraan dementia, xadgudubka iyo cudurada faafa, iyo khatarta sare ee kuwa kale, sida dhibaatooyinka dheefshiidka iyo pancreatitis (Xie, Choi iyo Al-Aly, 2025), laakiin cilmi baarista sida daaweynta ma muujin karaan sabab. Iyo laba tijaabooyin waaweyn oo ku saabsan cudurka Alzheimers hore, semaglutide afka ma hoos u dhac (Cummings et al., 2026). Kuwaas waa daawooyin xoog leh oo loogu talagalay cudurrada gaar ah; haddii ay ka yaraadaan da’da iyada ayaa la ogeyn.
Xaddidaadda Calorie
Xaqiiqada heerka: ballanqaad tijaabooyinka aadanaha
Cunista yar oo aan cunno xumo ku sii dheer nolosha noocyada badan, iyo waxaa la helay markii ugu horeysay “anti-da’da dhexdhexaadin”. In monkeys, labada cilmi-baaris weyn oo muddo dheer ah markii ugu horeysay u muuqday inay isku raacsan yihiin, laakiin falanqaynta wadajirka ah ayaa lagu soo gabagabeeyay in xaddidaadda kaloriin ay hagaajinayso caafimaadka iyo nolol marka faahfaahinta cuntada iyo da’da la tixgeliyo (Mattison et al., 2017). In CALERIE 2 baaritaan, 218 caafimaad qaba, dadka waaweyn ee aan miisaanka badan ayaa la weydiiyay inay cunaan 25 boqolkiiba ka yar laba sano oo ku saabsan 12 boqolkiiba. Dhiigkarkooda dhiigga, kolesteroolka iyo dareenka insulinta ayaa sii fiicnaa (Kraus et al., 2019), iyo mid ka mid ah tirakoobka dhaqdhaqaaqa da’da bini’aadamka, DunedinPACE, waxay hoos u dhacday 2 ilaa 3 boqolkiiba, in kasta oo laba saacadood oo kale aysan isbeddelin (Waziry et al., 2023). Calorie xaddidaadda waxay ku kacaysaa muruqyada iyo lafaha, oo ma aha mid ammaan ah dadka qaba ama khatarta ah ee cudurrada cunto, ama dadka waaweyn ee da’da yar.
Dib u dhigista dhiigga iyo plasma
Xujaynta heerka: hore ama speculative
Marka wareegyada ee mouse hore iyo gabar ayaa la wadaagay, qaar ka mid ah timaha mouse hore, sida muruqyada iyo liinta, dib u soo kabashada iyaga oo wanaagsan (Conboy et al., 2005). Mid ka mid ah protein dhiigga, GDF11, waxaa loo soo dhaweeyay sida ay tahay sababta da’da yar, laakiin shaqada dambe ma aysan soo saari karin natiijada (Egerman et al., 2015). Qaar ka mid ah cilmi-baarayaasha hadda waxay u maleynayaan in la yareeyo sababaha waxyeellada leh ee dhiigga qadiimiga ah ay muhiimad badan u leedahay in lagu daro kuwa yaryar: fiiro hore, kaliya ku beddelo nus biyo-mareenka xalka cusbada iyo albumin ayaa hagaajinaya muruqyada, xididdada iyo timaha maskaxda (Mehdipour et al., 2020). In trial yar oo placebo-ku-xiran, la soo noqnoqotay therapy plasma isbeddelka (soo celinta plasma la xalka albumin) wareegay dhowr saacadood epigenetic ujeedada da’da yar (Fuentealba et al., 2025), iyo in trial in cudurka Alzheimers waxay hoos u dhacay hoos u dhaca dhaqdhaqaaqyada maalinlaha ah ee dadka qaba cudurka dhexdhexaad ah (Boada et al., 2020). 2019, Maamulka Cuntada iyo Daawooyinka ee Mareykanka ayaa dadweynaha uga digay in daaweynta plasma ka timid deeq bixiyayaasha dhalinyarada ah aysan lahayn “maamuus caafimaad oo la xaqiijiyay” oo ay leeyihiin khatar dhab ah (FDA, 2019).
Saacadaha epigenetic: miisaanka da’da bini’aadamka
A qalab miisaanka, ma aha daawo
Si aad u tijaabiso haddii waxba ka yaraato da’da, cilmi-baarayaasha u baahan yihiin hab ay ku miisaanaan iyada oo aan la sugayo qarniyo. Saacadaha epigenetic akhriya calaamadaha kiimikada (methylation) at boqolaal meelood ee DNA iyo qiyaasta da’da laga bilaabo qaabka. Midka hore, by Steve Horvath, ka shaqeeyay in ka badan toban timaha (Horvath, 2013; Hannum et al., 2013). Ka dibna saacadaha waxaa lagu tababaray in ay saadaaliyaan caafimaadka ka badan da’da taariikhda: PhenoAge (Levine et al., 2018), GrimAge, oo si xoog leh u saadaalinayaa waqtiga dhimashada (Lu et al., 2019), iyo DunedinPACE, oo qiimeeya sida degdega ah ee qofku yahay inuu hadda qaato, sida speedometer (Belsky et al., 2022). Dadka saacadaha ka hor socda da’dooda ma dhintaan horay ku dhexdhexaad ah (Chen et al., 2016).
Waxay weli noo sheegi karin: haddii ay saacaddii dib u dhigto qof caafimaad qaba. Daaweynta ayaa lagu bedeli karaa calaamadaha aan la beddelin biyoolojiga hoostiisa. Saacadaha sidoo kale waxay noqon karaan kuwo qaylo badan: tusaale dhiig oo la isku mid ah oo laba jeer la miisaamiyey ayaa akhrinta siiyay ilaa sagaal sano oo kala duwan, in kasta oo noocyada casriga ah ee casriga ah ay yareeyaan tan (Higgins-Chen et al., 2022). Cuntada “da’da Biological” tijaabooyinka kala duwan oo aad u badan oo aan la siin waa in ay hoggaamiyaan go’aannada caafimaadka.
Maxaa la muujiyey maanta dadka
Xujo heerka: la xaqiijiyay in dadka
Iyadoo cilmiga kor ku xusan uu sii kordhayo, caddaynta ugu xoogan ee sanadihii caafimaad qabka ahaa ayaa ka yimaada dhaqanada iyo daawooyinka lagu tijaabiyay dad tiro badan. Midkoodna ma beddelo da’da, laakiin waxay si wada jir ah u dib u dhigaan cudurrada da’da ee sanadihii, iyo kuwa badankoodu wax yar ama waxba kuma jiraan.
Shaqooyinka jirka. Ururka Caafimaadka Adduunka wuxuu ku talinayaa 150 ilaa 300 daqiiqo oo hawlo dhexdhexaad ah, ama 75 ilaa 150 daqiiqo oo hawlo xoog leh, todobaad kasta, iyadoo la xoojinayo muruqyada laba maalmood ama ka badan iyo, dadka waaweyn, tababarka miisaanka si looga hortago dhacdooyinka. Shaqooyinka caadiga ah waxaa la xiriira khatarta hoose ee cudurka wadnaha, xanuunka wadnaha, nooca 2-aad ee sonkorowga, kansarka, niyad jabka iyo maskaxda (WHO, 2020). Tababarka xoogga dhisa muruqyada da’ kasta.

Ha sigaar cabin. Dadka ka joojiya sigaarka ka hor inta aan la gaarin da’da 40 jir waxay ka fogaan karaan in ka badan 90% khatarta dhimashada dheeraad ah ee sii socoshada (Jha et al., 2013). Joojinta da’ kasta oo caawiya.
Cirracka dhiigga iyo kolesteroolka. Imtixaankii SPRINT, xakamaynta adag ee cadaadiska dhiigga ayaa yareysay dhacdooyinka wadnaha iyo dhimashada, waxayna yaraysay cudurrada maskaxda (SPRINT MIND, 2019). Dhiig-karka sare badanaa ma laha calaamado, sidaa darteed miisaanka waa habka kaliya ee la ogaado.

Diet. Imtixaanku PREDIMED, cuntada Mediterranean oo lagu daray saliid saytuun ama khudradda ayaa hoos u dhigay dhacdooyinka wadnaha iyo xididdada dhiigga ee ku saabsan boqolkiiba 30 marka la barbardhigo cunto-xad-dhaaf ah (Estruch et al., 2018). WHO waxay sheegtaa in heerka khamriga uusan caafimaad u nabadgalyo ahayn; ka yar ayaa ka fiican.
Sleep. Dadka waaweyn waxaa lagula talinayaa in ay hurdaan ugu yaraan toddoba saacadood habeenkii si joogto ah (Watson et al., 2015); muddo dheer oo gaaban ama hurdo qalafsan ayaa la xiriira cudurrada wadnaha iyo metabolic, iyo hurdo apnea waa caadi iyo daawayn karo.
Xogta Bulshada. In weyn meta-qaadashada, dadka la xiriira xiriirka bulshada xoog badan oo ku saabsan 50 boqolkiiba ka sii badan u suurtogal ah in ay noolaadaan muddo daraasadda (Holt-Lunstad et al., 2010).
Maqaal, aragti iyo tallaalka. Maqalka oo lumiyay waa mid ka mid ah sababaha ugu weyn ee khatarta ah ee lagu bedeli karo cudurka maskaxda ee ay aqoonsadeen Guddiga Lancet, kaas oo xiriiriya 45 boqolkiiba xaaladaha maskaxda ee 14 sababaha la bedeli karo (Livingston et al., 2024). Imtixaanku wuxuu ku guuleystay, dhexdhexaadin maqal ah oo hoos u dhigay hoos u dhaca aqooneed ee ku saabsan 48 boqolkiiba saddex sano oo ka badan dadka waaweyn ee khatarta sare leh (Lin et al., 2023). Tijaabo dabiici ah oo Wales ka helay in tallaalka shimbiraha waxaa raacay ku saabsan 20 boqolkiiba yar dementia daaweynta toddoba sano (Eyting et al., 2025).

Marka meelaha oo dhan isbedelka. Natiijooyinka ugu weyn ayaa yimid marka bulshada la isbedelay. In North Karelia, Finland, barnaamij gobol oo dhan ka 1972 sigaarka, kolesteroolka iyo cadaadiska dhiigga, iyo dhimashada ka dhashay cudurka wadnaha ee dadka da’doodu u dhaxayso 35 ilaa 64 ayaa hoos ugu dhacay boqolkiiba 82 ragga iyo boqolkiiba 84 dumarka by 2012 (Jousilahti et al., 2016; Puska et al., 2016). Ka dib markii Scotland mamnuucay sigaar cabista meelaha dadweynaha la xiray ee 2006, isbitaal ku soo galay weerarada qalbiga iyo angina aan xasilloonayn hoos u dhacay by 17 boqolkiiba sanad (Pell et al., 2008). Finland ee FINGER tijaabo, laba sano oo barnaamij ah cuntada, jimicsi, tababarka maskaxda iyo baaritaanada wadnaha ayaa hagaajiyay fikirka iyo xusuusta dadka ku jira khatarta dementia (Ngandu et al., 2015), iyo in Taketoyo, Japan, dadka waaweyn ee ka qayb galay salons bulshada waxaa la sheegay inay ku dhow yihiin kala badh sida ay u badan tahay in ay horumariyaan cudurka shan sano ka badan (Hikichi et al., 2015).
Inta ugu xoog badan ee dhexdhexaadinta nolosha dheer ee la tijaabiyey waxba kuma jiraan: dhaqdhaqaaq, hurdo, aan sigaar cabin iyo ku noolaanshaha xiriirka. Cilmiga cusub wuxuu ujeedadiisu tahay in lagu daro iyaga, ma aha inay ka bedelaan.
Sida dheer nolosha caafimaad leh ayaa dadka u beddeli lahaa
Dunidu waxay ku socotaa wareeg degmo oo aan horey u dhicin. Sida ay sheegtay Qaramada Midoobay, heerka dhalmada adduunka waa hadda 2.25 dhalasho haweeney kasta oo ka hooseeya 3.31 ee 1990; in ka badan nus ka mid ah dalalka iyo gobollada oo dhan waxay leeyihiin dhalmada hoos u dhac ku yimid heerka lacagta 2.1, iyo in ka badan hal shan ka hooseeya 1.4. Dadka adduunka, 8.2 bilyan oo ah 2024, waxaa la saadaalinayaa in ay kor u kacdo ilaa 10.3 bilyan inta u dhaxaysa 2080 iyo hoos u dhaca yar ee 10.2 bilyan by 2100. In 63 dal iyo gobol, oo leh 28 boqolkiiba dadka, tirada dadku waa horey u korsaday. Sannadkii 2070-kii, dadka da’doodu tahay 65 iyo ka badan ayaa la saadaalinayaa inay ka badan yihiin carruurta da’doodu ka yar tahay 18 (UN World Population Prospects 2024). Sababaha dhalmada hoos u dhaca, iyo sababta Local Solar System Foundation taageero waxbarashada iyo doorasho dhab ah oo loogu talagalay qoyska oo dhan, waxaa lagu qeexay boggayaga ku saabsan dadka, isticmaalka iyo kheyraadka.
Dadka da’da weyn ayaa badanaa loo qeexaa sida culays: shaqaalaha ka yar taageeraya mushaharka dheeraad ah. Miisaanka caadiga ah, raacyada ku tiirsanaanta da’da, waxay tirinaysaa dadka da’doodu tahay 65 iyo ka badan oo leh 100 qof oo da’doodu u dhaxayso 20 ilaa 64. Tirada dadka dunida ku nool ee laga soo xigtay hay’adda Qaramada Midoobay ayaa ah 18 milyan oo qof sannadka 2024, waxaana la filayaa inay gaadhi doonaan 29 milyan sanadkii 2050 iyo 44 milyan sanadkii 2100; Japan waxaa hadda jira 55 milyan (UN World Population Prospects 2024).
Da’da waa ma aha tirada go’an
In tallaabada ay u maleynayaan in 65-sano jir ah oo 2100 noqon doonaa sida xanuunsan sida 65-sano jir ah ee 1950. Demographers Warren Sanderson iyo Sergei Scherbov ayaa sheegay in tani ay been abuur tahay. Waxay soo jeediyeen in la cabiro da’da sanadihii ay dadka ka tageen inay noolaadaan, oo aan ahayn sanadkii ay noolaayeen, waxayna muujiyeen in dadku ay “ugu yaraan karaan” tallaabadan xitaa marka da’dooda qiyaasta ah ay kor u kacdo (Sanderson iyo Scherbov, 2005; Sanderson iyo Scherbov, 2010). Mid ka mid ah noocyada soo saaro xadka da’da halkaas oo nolosha la filayo ee haatan jira hoos u dhaca 15 sano: haweenka Faransiiska, taas oo ahayd 58 in 1900 iyo ku dhowaad 75 in 2012 (Sanderson iyo Scherbov, 2015).
Erayga muhiimka ah waa healthy. Adduunka oo dhan, nolosha la filayo waxay ka kori doontaa 66.8 ilaa 73.1 sano inta u dhexeysa 2000 iyo 2019, halka kala duwanaanta u dhaxaysa nolosha la filayo iyo nolosha caafimaad qabta ay ka sii ballaaran tahay 8.5 ilaa 9.6 sano (WHO Global Health Observatory; Garmany iyo Terzic, 2024). Sannadaha dheeraadka ah ee la qaatay caafimaad xumo ma kordhiyaan cadaadiska ku jira qoysaska iyo nidaamka caafimaadka. Sannadaha dheeraadka ah ee caafimaad wanaagsan ayaa kala duwan: dadka waxay sii wadi karaan shaqada haddii ay rabaan, ka shaqeeyaan kuwa kale, ku deeqaan, bartaan oo gacan ka geystaan. Taasi waa sababta cilmiga ku qoran boggani muhiim u ah dadka, ma aha oo kaliya dadka.
Chart kor ku xusan waa tusaale, ma aha saadaalin. Waxay isticmaalaan tirada dadka ee la saadaaliyey ee Qaramada Midoobay waxayna weydiiyaan su’aal kaliya: haddii dadku ay helaan sano caafimaad leh iyo da’da ay caadi ahaan joojiyaan shaqada oo ay u baahan yihiin taageero dheeraad ah oo ay la socdaan, sidee bay isbeddeli doontaa miisaaniyadda? Haddii line ka tagay 65 ilaa 70, dunida 2100 waxaa ku saabsan 31 dadka waaweyn oo dhan 100 ee da’da shaqada ee aan ahayn 44; at 75, ku saabsan 21, u dhow heerka maanta. Faallo waa weyn: in sano dheeraad ah oo caafimaad qaba, in shaqada iyo mushaharka la jaan qaada, iyo in guusha gaadho qof kasta, ma aha kuwa dhaqaalaha leh oo keliya.
Ka dib, waalidiinta caafimaad qaba
Waalidku waxay leeyihiin carruur ka dib oo dhan. Wadamada OECD, da’da qiyaasta ah ee hooyada marka ay dhashaan markii ugu horeysay waxay ka kor u kacday 26.4 sanadkii 2000 ilaa 29.6 sanadkii 2024 (OECD Family Database). Oogaas muujiyaan da’da ka hor inta aan timaha kale ee badan ee jirka (Garrison, 2026), iyo hoos u dhac ku yimaado dhalmada in la soo dhaafay saddexdan iyo afartanka xaddidaya sida carruurta oo dadka oo bilaabay ka dib ay leeyihiin. Cilmi baarista ku saabsan da’da soo noqnoqda waa hadda qayb ka mid ah geroscience: tusaale ahaan, tijaabada VIBRANT ee Jaamacadda Columbia tijaabiyey haddii low-doos rapamycin ay yareeyaan luminta uurka haweenka da’doodu u dhaxayso 35 ilaa 45 (ClinicalTrials.gov NCT05836025); natiijooyinka weli lama daabacin. Haddii da’da uurka leh si nabad ah loo yareyn karo, dadka doonaya carruurta waxay u yeelan karaan iyaga ka dib, aan la qabsan cadaadiska furitaanka.
Maxaa demographers badani u maleynayaan hoos u dhac ku dambayn
Waa muhiim in la run sheego oo ku saabsan aragtida ka soo horjeedka. Dhibaatooyinka Caalamiga ah ee Cudurrada ayaa rajaynaya 155 ka mid ah 204 waddamada iyo gobollada inay leeyihiin uurka hoostiisa ku soo laabashada 2050 iyo 198 by 2100; oo ka mid ah 47 dalal oo uurku uu soo noqnoqda, saddex keliya ayaa dib ugu noqday bedelka korkiisa (GBD 2021 Fertility and Forecasting Collaborators, 2024). Qaramada Midoobay waxay go’aansatay in dalalka uurka yar oo tiradoodu kor u kacday ay aad uga fog yihiin inay 30 sano gudahood dib ugu noqdaan (UN World Population Prospects 2024). Qaar ka mid ah demographers sharaxayaa suurtogal ah low-dhiig-dhac, oo ay ku jiraan qarniyo yaryar, yar yar oo qoyska ugu fiican iyo cadaadis dhaqaale si wadajir ah u xoojiyaan (Lutz, Skirbekk iyo Testa, 2006), iyo ekonomists Dean Spears iyo Michael Geruso sheegaan in haddii aan la bedelin, tirada dadka adduunka ee ay hoos u dhici kartaa muddo dheer ka dib markii uu kor u (Spears iyo Geruso, 2025). Nolosha dheer oo keliya ma xalliyo arrintan: waxay hoos u dhacaan, laakiin muddada dheer ee tirada dadka oo ay ku jiraan dhalashada yar ayaa weli yaraada.
Tilmaamkeena: hoos u dhaca waa dhibaato waqti
aragtida Local Solar System Foundation waa in hoos u dhaca tirada dadka waa dhibaato waqti ah, isbedelka si ay u dhaqmaan oo aan ahayn xaalad degdeg ah. Waxaan soo bandhigi sida faahfaahin, sababaha iyo caddayn in ay muujiyaan waa sax ama khalad.
Talogelinta.
- Nolosha caafimaad leh ee dheer waxay ka dhigan tahay dhalmo yar oo loo baahan yahay si ay u ahaadaan dad joogto ah. Dadka aan kobcin ama yarayn, miisaankeeda waa la mid ah tirada dhalashada sanad kasta oo lagu kordhiyo nolosha la filayo marka la dhinto, aqoonsi aasaasiga ah oo ah demography (Preston, Heuveline iyo Guillot, 2001). Haddii nolosha la filayo kor u kacay ilaa 73 sano oo ku saabsan 90, dadka isku mid ah waxaa lagu sii wadi karaa in ay ku saabsan hal shan meelood meel oo dhasha ka yar sanad kasta.
- Saxaafadda, aan da’da, go’aamiya cidda u baahan taageero. Haddii geroscience dib u dhigeysa cudurrada da’da by xitaa dhowr sano, saamiga ku tiirsanaanta gaarka ah waxay ku sii jiri kartaa dhawr maalmood oo maanta in kastoo sida dadka waaweyn ee kor ku xusan, sida chart sare muujinaya.
- A dheer oo dhalmada daaqadda ka dhigi kara dadka inay carruur ay rabaan. Haddii uurka da’da la yareyn karo si ammaan ah, ka dib waalidiinta ma noqon doono in ka yar carruurta.
- Dhiig-baxnimadu waxay soo kabatay horay. Wadamada ugu horumarsan, cilmi baadhisyo qaar ayaa ogaadey in horumarka sii kordhaya ee horumarinta uu la xiriiray kor u kaca dhalmada (Myrskylä, Kohler iyo Billari, 2009), gaar ahaan halkaas oo shaqada iyo nolosha qoyska ay ka fududahay in la isku daro (Luci-Greulich iyo Thévenon, 2014), inkastoo tani ay tahay mid muran badan leh (Harttgen iyo Vollmer, 2014).
- A hoos u dhac yar oo waqti si ay u dhaqmaan. Qaramada Midoobay ayaa saadaaliyay sare u kac xawaare hooseeya iyo hoos u dhac yar ee qarnigii, ma aha burburka, taas oo ka tagta sano badan cilmiga, shaqada iyo siyaasadda qoyska si ay u dhaqmaan.
Maxaa tijaabi lahaa. Farqiga wuxuu heli doonaa taageero haddii: nolosha caafimaad qaba ee la filayo ayaa kor u kacaysa si degdeg ah oo ka badan nolosha la filayo, xiran farqiga; dacwad muujinaysa in mid ka mid ah dhexdhexaadinta dib u dhigto cudurrada qaarkood ee da’da isla markiiba, sida TAME loo sameeyay inay sameeyaan; dhalashada da’da weyn waxay kor u qaadaan si ay u dhammaystiraan miisaanka qoyska oo joojiyay hoos u dhaca; iyo saadaasha ku tiirsanaanta da’da wayn ee lagu cabiro caafimaadka, oo aan ahayn da’da go’an, sii xasilloon. Waxay noqon doontaa la yareeyay haddii ay ka fog tahay sanadka caafimaad qaba sii ballaadhin, haddii tijaabooyinka ugu horeysay ee rapamycin, senolytics iyo reprogramming ku fashilmaan, iyo haddii uurka sii hoos u dhacaan xitaa halkaas oo waalidiinta ay leeyihiin muddo dheer, nolosha caafimaad leh, taageero wanaagsan iyo doorasho dhab ah. Waxaan raaci doonaa caddayn iyo cusbooneysiinta boggaan sida ay timaado.
Adduunka oo ay ku jiraan dad yar, oo nool muddo dheer ayaa sidoo kale ka mid ah kuwa ugu fudud adduunka, taas oo ah sababta su’aashan ay la xiriirto Local Solar System Foundation ee shaqada heshiiska dadka iyo kheyraadka.
Fiiro gaar ah u yeesha: daawooyinka, isbitaalada iyo isku-xirka
Ururada samaynta shaqadan
Ururadaan aan faa’iido doonka ahayn waxay daabacaan waxa ay sameeyaan iyo warbixinno ku saabsan natiijooyinka la xisaabtami karo. Haddii aad rabto inaad taageerto caafimaadka iyo da’da, fadlan eeg shaqada ay hayaan oo ka fikir si toos ah u siintooda, iyaga oo isticmaalaya bogagga internetka. Local Solar System Foundation ma laha xiriir la mid ah mid ka mid ah oo waxba kama hesho iyaga. Ka hor intaadan bixin, akhriso warbixinnada iyo xisaabaadka sanadlaha ah ee urur kasta.
- HelpAge International (Boqortooyada Midowday, hay’ad samafal oo diiwaangashan 288180). Waxay la shaqeysaa ururo saaxiibo ah oo ka jira dalalka badan si dadka waaweyn ay u helaan daryeel caafimaad, daryeel bulsho iyo ilaalinta dakhligooda, waxayna ka hadlaan xuquuqda dadkaas.
- Age UK (Britain, diiwaan gashan samafalka 1128267). Waxay bixisaa taageero dhab ah dadka waaweyn ee la kulma nafaqo, kala go’a iyo xadgudubka, iyo cilmi baarista iyo olole doorasho oo wanaagsan.
- British Heart Foundation (Boqortooyada Midowday, hay’ad samafal oo diiwaan gashan 225971). The ugu weyn ee madaxbannaan maalgelinta cilmi baarista ku saabsan xanuunka qalbiga iyo wareega ee UK.
- American Heart Association (Mareykan, canshuur-exempt aan faa’iido doon ahayn). Lacagta cilmi baarista cudurrada wadnaha iyo xanuunka wadnaha iyo barnaamijyada bulshada ee ka hortagga.
- Alzheimer’s Society (Britain, deeqda diiwaangashan 296645) iyo Alzheimer’s Association (United States, tax-exempt aan faa’iido doon ahayn). Labaduba taageeraan dadka ku nool cudurka maskaxda iyo kuwa u adeega, oo maalgeliya cilmi baarista ka hortagga, daaweynta iyo daryeel.
Sideed u caawin kartaa
- Bilaaw waxa la xaqiijiyay. U dhaqaaq wax yar oo ka badan maanta, ku dar xoog iyo miisaanka jimicsiga, oo weydiiso xirfadle caafimaad si aad u hubiso cadaadiska dhiigga.
- Ilaawin maqalkaaga iyo indhahaaga, oo dhiirrigeli waalidiintaada iyo walaalahaaga inay sidaas sameeyaan.
- La xiriir. Wici qof aad la hadalka ah muddo; u yeedha deris ka fog waxba.
- Follow tijaabooyinka, ma adverts. Natiijooyinka ka tijaabooyin diiwaangashan, oo lagu daabacay wargeysyada la isku raacsan yahay, waa waxa xisaabta.
- Laa yaab leh ee mucjiso sheegashada, iyo qaybinta this page marka aad aragto mid.
- Na caawi inaad si sax ah u ilaaliso bogga. Cilmi-baarayaasha, dhakhaatiirta iyo tarjumayaashu waxay ku deeqi karaan qaybqaadashada guddiga.
Xogta iyo akhriska dheeraadka ah
- Kennedy iyo al. (2014), Geroscience: isku xirka da’da iyo cudurka joogtada ah, Cell 159
- Lopez-Otin et al. (2013), Cidna ma oga in aad uur leedahay, Cell 153
- Lopez-Otin et al. (2023), Hallmarks of aging: an expanding universe, Cell 186
- Goldman et al. (2013), Sacuudiga iyo dhaqaale soo noqnoqda ka dib markii da’da ayaa laga yaabaa in ay sabab u tahay diiradda cusub ee cilmi baarista caafimaadka, * Arrimaha Caafimaadka * 32
- Scott, Ellison iyo Sinclair (2021), Qiyaasta dhaqaalaha ee lagu bartilmaameedsanayo da’da, Nature Aging 1
- Xarunta Qaranka ee Tirakoobka Caafimaadka (2026), NHIS Tirakoobka Caafimaadka Dadweynaha, 2025, iyo NHIS 2025 faylka tusaalaha ah ee dadka waaweyn
- Jaamacadda Qaranka ee Kansarka, SEER*Explorer, cudurrada kansarka oo ku saleysan da’da, 2019 ilaa 2023
- Manly et al. (2022), Qiyaasta faafitaanka cudurka maskaxda iyo cudurka maskaxda ee Mareykanka, JAMA Neurology 79
- Garmany iyo Terzic (2024), Guud ahaan caafimaadka-lifespan kala fogaansho ka mid ah 183 ururka caafimaadka adduunka ee xubnaha ka ah dalalka, JAMA Network Open 7
- Jaamacadda Qaranka ee Mareykanka ee Da’da, Interventions Testing Program
- Vézina, Kudelski iyo Sehgal (1975), Rapamycin (AY-22,989), antibiyootiko cusub oo antifungal ah, Journal of Antibiotics 28
- Harrison iyo al. (2009), Rapamycin oo la siiyay nolosha ayaa sii kordhisa nolosha fidinta ee fiidyaha jeermiska ah, Nature 460
- Miller iyo al. (2011), Rapamycin, laakiin ma resveratrol ama simvastatin, kordhisaa nolosha dheer ee faraska jeermiska heterogeneous, * Journals of Gerontology A * 66
- Miller iyo al. (2014), Rapamycin-midowga nolosha kordhinta fidrada waa daawo iyo jinsiga ku xiran, * Aging Cell * 13
- Mannick et al. (2014), mTOR xakamaynta hagaajinta shaqada difaaca ee dadka waaweyn, * Cilmiga Translational Medicine * 6
- Mannick et al. (2018), TORC1 xakamaynta waxay xoojisaa shaqada difaaca jirka oo yareysaa cudurrada dadka waaweyn, * Cilmi-baarista Cilmi-baarista * 10
- Mannick et al. (2021), Isku dayga biolojiyada da’da oo leh daawooyinka mTOR si loo wanaajiyo shaqada difaaca ee dadka waaweyn: tijaabooyin la isku halleyn karo oo ah heerka 2b iyo heerka 3, *Lancet Longevity Healthy * 2
- Moel et al. (2025), Tabarta rapamycin ee nabadgelyada iyo miisaanka caafimaadka sanad ka dib: Natiijooyinka baaritaanka PEARL, Da’da 17
- Lee, Kuerec iyo Maier (2024), [Targetaging da’da rapamycin iyo alaabooyinka ka soo baxa dadka: dib u eegista habsami leh](https://doi.org/10.1016/S2666-7568(23) 00258-1), * Lancet Longevity caafimaad qaba * 5
- Lamming et al. (2012), Rapamycin-induceed insulin resistance waa mid dhexdhexaad ah oo ay sabab u tahay mTORC2 dhimashada iyo kala go’i ka dib nolosha dheer, * Science * 335
- US National Library of Medicine, DailyMed: sirolimus daaweynta macluumaad
- Coppé et al. (2008), fenotypes-ka la xiriira ee la xiriira waxay muujinayaan shaqooyinka RAS ee aan madaxbannaanayn ee oncogenic iyo p53 oo ku jira unugyada, * PLOS Biology * 6
- Baker iyo al. (2011), Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders, Nature 479
- Baker iyo al. (2016), Natuur ahaan ka dhaca p16Ink4a-celuliyada wanaagsan yareeyaan nolosha caafimaad qaba, Nature 530
- Zhu et al. (2015), Tallaalka Achilles ee unugyada senescent: ka soo jeeda transcriptome ilaa daroogada senolytic, * Aging Cell * 14
- Xu et al. (2018), Senolytics hagaajiya shaqada jirka iyo kordhinta nolosha da’da, Nature Medicine 24
- Yousefzadeh et al. (2018), Fisetin waa senotherapeutic oo kordhisa caafimaadka iyo nolosha, * EBioMedicine * 36
- Cadaaladda et al. (2019), Senolytics in idiopathic pulmonary fibrosis: natiijooyinka ka soo baxa cilmi-baaris ugu horreysa oo bini’aadam ah, laab furan, daraasad tijaabo ah, EBioMedicine 40
- Hickson et al. (2019), Senolytics waxay yareeyaan unugyada da’da ee dadka, EBioMedicine 47
- Farr et al. (2024), Faa’iidooyinka daaweynta senolytic ee kala-guurka lafaha haweenka postmenopausal: tijaabo 2 oo loo habeeyay oo loo habeeyey, Nature Medicine 30
- Gonzales et al. (2023), Daaweynta Senolytic ee cudurka Alzheimer’s ee fudud: tijaabo faa’iido leh oo ah 1, Nature Medicine 29
- Unity Biotechnology (2025), ASPIRE heerka 2b natiijooyinka topline iyo sharciga kala furfurnaanta, US Securities iyo Exchange Commission files
- Mills iyo al. (2016), Maamulka dheer ee nicotinamide mononucleotide wuxuu yareeyaa hoos u dhaca jirka ee la xiriira da’da firfircoon, *Cell Metabolism * 24
- Zhang et al. (2016), NAD + buuxinta waxay hagaajineysaa shaqada mitochondrial iyo unugyada jirka oo kordhisa nolosha firfircoon ee fiiriyaha, * Sayniska * 352
- Harrison iyo al. (2021), 17-a-estradiol oo nolosha ku dambaysa ayaa kordhisa nolol maalmeedka firfircoonida UM-HET3 firfircoon; riboside nicotinamide iyo saddex daroogada kale ma saameynayaan nolol maalmeedkooda labada jinsi, Aging Cell 20
- Martens et al. (2018), Nicotinamide riboside oo joogto ah ayaa si fiican loo dulqaadan karaa oo kor u qaadaysa NAD + dadka waaweyn ee da’doodu tahay iyo kuwa ka weyn, Nature Communications 9
- Yoshino et al. (2021), Nicotinamide mononucleotide waxay kordhisaa dareenka muruqyada ee haweenka qaba cudurka sonkorowga, Science 372
- Brakedal et al. (2022), Baaritaanka NADPARK: tijaabo la isku halleyn karo oo ah nicotinamide riboside oo lagu daro cudurka Parkinson, *Cell Metabolism * 34
- Zhang et al. (2025), Taageerada nicotinamide mononucleotide ee afka ah ee ku saabsan glucose iyo metabolismka lipid ee dadka waaweyn: dib u eegista habsami leh, * Dib u eegista muhiimka ah ee Sayniska Cuntada iyo Cunnada * 65
- Prokopidis et al. (2025), Tacaabada nicotinamide mononucleotide iyo riboside ee muruqyada muruqa iyo shaqada, *Journal of Cachexia, Sarcopenia and Muscle * 16
- Maamulka Cuntada iyo Daawooyinka Mareykanka (2025), wax ka beddelka codsiga muwaadinka ee NMN, docket FDA-2023-P-0872
- Howitz et al. (2003), Moleculars yaryar ee sirtuins sii dheereeya Saccharomyces cerevisiae nolosha, Nature 425
- Baur et al. (2006), Resveratrol hagaajiyaa caafimaadka iyo nolol maalmeedka ee faraha ku saabsan cuntada sare-kalori, Nature 444
- Pearson et al. (2008), Resveratrol dib u dhac ku saabsan da’da iyo xusuusta dhinacyada transcriptional ee xaddidaadka cuntada aan la kordhin nolosha, * Cell Metabolism * 8
- Kaeberlein et al. (2005), substrate-soo celinta gaar ah ee sirtuins by resveratrol, * Journal of Biological Chemicals * 280
- Pacholec et al. (2010), SRT1720, SRT2183, SRT1460, iyo resveratrol ma aha kuwa ku shaqeeya si toos ah SIRT1, * Wargeyska Biological Chemicals * 285
- Burnett iyo al. (2011), Ka maqnaanshaha saameynta Sir2 overexpression on nolosha C. elegans iyo Drosophila, Nature 477
- GlaxoSmithKline iyo Sirtris Pharmaceuticals (2008), warbixinta dalabka tartanka, Guddiga Lacagta iyo Is-weydaarsiga Mareykanka
- Kanfi et al. (2012), Sirutin SIRT6 wuxuu xakameeyaa nolosha firfircoon ee fiidyaha labka ah, Nature 483
- Roichman et al. (2021), Dib-u-habeynta homeostasis-ka tamarta ee SIRT6 waxay kordhisaa nolosha caafimaad qaba, Nature Communications 12
- Abaalmarinta Nobel ee Fisiolojiga ama Daaweynta 2009 iyo 2012
- Bernardes de Ciise et al. (2012), Telomerase daaweynta jirka ee dadka waaweyn iyo firfircoon fardaha ka dibna waa in la sii daayo oo kor u qaada nolosha dheer iyada oo aan kordhin kansarka, * EMBO Molecular Medicine * 4
- Kim et al. (1994), Xildhibaan gaar ah oo ka tirsan hawlgalka telomerase ee aadanaha leh unugyada aan dhimanayn iyo kansarka, Science 266
- Telomeres Mendelian randomization la shaqeynta, Haycock et al. (2017), Xariirka u dhexeeya dhererka telomere iyo khatarta kansarka iyo cudurada aan neoplastic ahayn, *JAMA Oncology * 3
- Armanios iyo Blackburn (2012), The telomere syndromes, Nature Review Genetics 13
- Townsley et al. (2016), Danazol daaweynta cudurrada telomere, NEJM 374
- Takahashi iyo Yamanaka (2006), Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell 126
- Ocampo et al. (2016), In vivo hagaajinta astaamaha da’da la xiriira iyadoo lagu daro qaybo ka mid ah, *Cell * 167
- Lu iyo al. (2020), Dib u soo celinta xogta epigenetic ee dhalinyarada ah iyo soo celinta aragtida, Nature 588
- Browder et al. (2022), In vivo qayb ka mid ah dib u soo celinta ayaa wax ka beddelaysa isbedelada molekyulka ee la xiriira da’da inta lagu jiro da’da fisiologiga ah ee fidnada, Nature Aging 2
- Macip et al. (2024), Dib-u-soo-celinta qaybta ah ee daaweynta jeermiska ayaa kordhisa nolosha iyo dib u dhigista isbeddellada la xiriira da’da ee fidinta da’da, *Cellular Reprogramming * 26
- Abad et al. (2013), Reprogramming in vivo waxay soo saartaa teratomas iyo unugyada iPS oo leh astaamo totipotency ah, Nature 502
- Parras et al. (2023), In vivo reprogramming waxay keenaysaa dhimasho hore oo la xiriirta cudurka sonkorowga iyo cudurrada caloosha, Nature Aging 3
- Life Biosciences (2026), FDA ogolaansho ka IND ER-100 iyo dhiig xanuunka ugu horeysay; tijaabo record NCT07290244
- Warbixinnada shirkadda: Altos Labs (2022), Retro Biosciences (2026), NewLimit (2026); iyo MIT Technology Review (2023) on Retro Biosciences
- Jiang et al. (2025), eegista Barnaamijka Imtixaannada Dhexdhexaadinta, Journals of Gerontology A 80
- Harrison iyo al. (2014), Acarbose, 17-α-estradiol, iyo acid nordihydroguaiaretic waxay kordhiyaan nolosha farta ee ragga, * Aging Cell * 13
- Xoogan et al. (2016), Nolosha dheer ee fidrada labka ah oo lagu daweeyo agonist estrogenic oo yar, anti-oxidant, inhibitor α-glucosidase ama Nrf2-inducer, *Aging Cell * 15
- Xoogan et al. (2008), Nordihydroguaiaretic acid iyo aspirin kordhinta nolosha ee faraska jinsiga ah ee jinsiga ah, * Aging Cell * 7
- Miller iyo al. (2019), Glycine supplementation waxay kordhisaa nolosha firfircoon ee faraha labka iyo dheddigga, Aging Cell 18
- Miller iyo al. (2020), Canagliflozin wuxuu kordhiyaa nolosha jirka ee jirka ah laakiin aan ahayn faraska dumarka ah, * JCI Insight * 5
- Xoogan et al. (2022), faa’iidooyinka nolosha ee isku-dhafka rapamycin iyo acarbose iyo captopril ee faraska jeermiska ah ee kala duwan, * Aging Cell * 21
- Bannister iyo al. (2014), Ma dadka qaba nooca 2 sonkorowga noolaan karaan muddo dheer ka badan kuwa aan lahayn?, * Sonkorowga, Cudurka Sonkorowga iyo Metabolism * 16
- Barzilai et al. (2016), Metformin sida qalab si ay u bartaan da’da, * Cell Metabolism * 23
- Keys et al. (2022), Dib u qiimeynta caddaynta faa’iidada nolol maalmeedka nooca 2 ee cudurka sonkorowga oo lagu daweeyo metformin marka la barbardhigo kuwa aan sonkorowga lahayn, * Wargeyska Caafimaadka Caafimaadka Caafimaadka * 51
- Konopka et al. (2019), Metformin waxay ka hortagtaa isbeddellada mitochondrial ee tababarka jimicsiga aerobic ee dadka waaweyn, *Aging Cell * 18
- Walton iyo al. (2019), Metformin wuxuu ka hortagaa muruqyada hypertrophy si uu u jawaabo tababarka jimicsiga ee difaaca ah ee dadka waaweyn (MASTERS), *Aging Cell * 18
- Lincoff et al. (2023), Semaglutide iyo natiijooyinka wadnaha ee cudurka sonkorowga aan lahayn sonkorowga (SELECT), NEJM 389
- Xie, Choi iyo Al-Aly (2025), Mapping faa’iidada iyo khatarta GLP-1 agonists, Nature Medicine 31
- Cummings et al. (2026), Semaglutide afka ah ee cudurka Alzheimer’s ee hore (soo bandhig iyo soo bandhig +), The Lancet 407
- Mattison et al. (2017), Caloric xaddidaadda hagaajineysa caafimaadka iyo nolol maalmeedka rhesus monkeys, Nature Communications 8
- Kraus et al. (2019), 2 sano oo xaddidan oo kaloriin ah iyo khatarta cardiometabolic (CALERIE), * Lancet Diabetes & Endocrinology * 7
- Waziry et al. (2023), Taageerada xaddidaadda caloosha ee muddada dheer ee ku saabsan miisaanka DNA-ga ee da’da dabiiciga ah, Nature Aging 3
- Conboy iyo al. (2005), Rejuvenation of aged progenitor cells by exposure to a young systemic environment, Nature 433
- Mehdipour et al. (2020), Ka soo kabashada saddexda tiir ee timaha timaha ah iyadoo la isku beddelayo dhiigga dhiigga oo leh saliidda-albumin, Da’da 12
- Egerman et al. (2015), GDF11 kordhisa da’da iyo ka hortagta soo kabashada muruqyada skeletal, *Cell Metabolism * 22
- Fuentealba et al. (2025), Faahfaahinta Multi-omics waxay muujineysaa biomarkers oo ka qaybqaadanaya soo kabashada da’da bini’aadamka iyadoo loo jawaabayo isbeddelka plasma-da daaweynta, *Aging Cell * 24
- Boada et al. (2020), Baaritaanka bukaan socodka oo la isku halleyn karo oo lagu xakameeyo isbeddelka plasma iyo bedelka albumin ee cudurka Alzheimers (AMBAR), *Alzheimer’s & Dementia * 16
- Maamulka Cuntada iyo Daawooyinka Mareykanka (2019), Warbixin ka digaysa macaamiisha inay helaan daawo-bixiye yar oo plasma ah
- Horvath (2013), DNA methylation da’da timaha aadanaha iyo noocyada unugyada, * Genome Biology * 14
- Hannum et al. (2013), Sifooyinka methylation ee genome-ka oo dhan waxay muujinayaan aragtiyo tiro ah oo ku saabsan heerarka da’da aadanaha, *Molecular Cell * 49
- Levine iyo al. (2018), Biyo-markab epigenetic oo ah da’da nolosha iyo caafimaadka (PhenoAge), Da’da 10
- Lu iyo al. (2019), DNA methylation GrimAge si xoog leh u saadaaliyaa nolosha iyo caafimaadka, Da’da 11
- Belsky iyo saaxiibadaa. (2022), DunedinPACE, DNA methylation biomarker ee dhaqdhaqaaqa da’da, eLife 11
- Chen et al. (2016), Miisaanka DNA ee ku saleysan da’da bini’aadamka: falanqaynta meta ee saadaalinaya waqtiga dhimashada, Da’da 8
- Higgins-Chen et al. (2022), Xalka xisaabinta ee xoojinta kalsoonida saacadaha epigenetic, Nature Aging 2
- Hay’adda Caafimaadka Adduunka (2020), Tallaabooyinka ku saabsan dhaqdhaqaaqa jirka iyo hab-dhaqanka fadhiidnimada
- Jha et al. (2013), 21st-qarnigii khatarta sigaar cabista iyo faa’iidooyinka joojinta ee Mareykanka, NEJM 368
- SPRINT MIND Investigators (2019), Tacaabada xakamaynta cadaadiska dhiigga ee adag iyo heerarka caadiga ah ee ku saabsan cudurka maskaxda, JAMA 321
- Oyster iyo al. (2018), ka hortagga ugu horreeya ee cudurrada wadnaha iyo xididdada dhiigga oo leh cunto Mediterranean ah, NEJM 378
- Watson iyo al. (2015), Tirada lagula taliyey ee hurdada ee qof weyn oo caafimaad qaba, Sleep 38
- Holt-Lunstad et al. (2010), Xogta Bulshada iyo khatarta dhimashada, PLOS Medicine 7
- Livingston et al. (2024), ka hortagga, dhexdhexaadinta iyo daryeelidda cudurka maskaxda: 2024 warbixinta Guddiga joogtada ah ee Lancet, The Lancet 404
- Lin et al. (2023), Maqaal dhexdhexaadin ah oo ka dhanka ah xakamaynta waxbarashada caafimaadka si loo yareeyo hoos u dhaca aqoonta (SHAQADA), The Lancet 402
- Eyting et al. (2025), A dabiiciga ah tijaabo ku saabsan saameynta tallaalka herpes zoster on dementia, Nature
- Paluch et al. (2022), Tallaabooyinka maalinlaha ah iyo dhimashada dhammaan sababaha: falanqeyn meta ah oo ku saabsan 15 kooxood oo caalami ah, * The Lancet Public Health * 7
- et al. (2016), 40-sano CHD dhaqdhaqaaqyada dhimashada iyo doorka sababaha khatarta ah ee hoos u dhaca dhimashada: North Karelia Project dareen, * Qalbiga Adduunka * 11
- Puska et al. (2016), Dadka, qodobbada, hirgelinta iyo khibradaha guud ee mashruuca Karelia-da Waqooyi, Global Heart 11
- Vartiainen et al. (2010), Xildhibaan-sadex iyo toban sano ee isbeddelada sababaha khatarta ah ee wadnaha iyo xididdada dhiigga Finland, * International Journal of Epidemiology * 39
- Pell et al. (2008), Smoke-free sharciyada iyo isbitaallada sicir barar coronary acute, NEJM 359
- Ngandu et al. (2015), A 2 sano multidomain dhexdhexaadinta ka hortagga hoos u dhaca aqooneed ee dadka waaweyn ee khatarta ah (FINGER), * The Lancet * 385
- Hikichi et al. (2015), Taageerada barnaamij dhexdhexaadin bulsho oo dhiirigeliya isgaarsiinta bulshada ee ka hortagga cudurka maskaxda ee dadka waaweyn: daraasadda JAGES Taketoyo, Journal of Epidemiology and Community Health 69
- Qaramada Midoobay, Waaxda Arrimaha Dhaqaalaha iyo Bulshada, Qaybta Dadka (2024), Dadka Caalamka 2024: Faahfaahinta Natiijada iyo faylooyinka xogta
- Sanderson iyo Scherbov (2005), Average nolosha ka harsan ee ay kordhin kartaa sida dadka da’da, Nature 435
- Sanderson iyo Scherbov (2010), Remeasuring da’da, Science 329
- Sanderson iyo Scherbov (2015), kordhinta degdega ah ee nolosha aadanaha ayaa keeni karta in dadka da’da ahi ay yaraadaan, * PLOS ONE * 10
- Hay’adda Caafimaadka Adduunka, Global Health Observatory: nolosha la filayo iyo nolosha caafimaad qaba
- Xarunta Macluumaadka qoyska ee OECD, Da’da hooyada markay uur leedahay iyo dhalmada da’da ku xiran
- Garrison (2026), Beyond soo noqnoqoshada: oogaha sida nidaamka maareeya caafimaadka haweenka iyo da’da, * PLOS Biology * 24
- Cilmi baarista VIBRANT ee rapamycin iyo uurka, ClinicalTrials.gov NCT05836025
- GBD 2021 Waxsoosaar iyo Qorshaha La-shaqeeyaha (2024), Dhadhanka adduunka ee 204 dal iyo gobol, 1950 ilaa 2021, oo leh saadaal ilaa 2100, The Lancet 403
- Lutz, Skirbekk iyo Testa (2006), Xaqiiqda ah in uurka yar yahay, Wienna Yearbook of Population Research
- Spears iyo Geruso (2025), Ka dib markii Spike: Dadka, Horumarinta, iyo kiiskan dadka, Simon & Schuster
- Preston, Heuveline iyo Guillot (2001), Dheegashada: Miisaanka iyo Modeling dhaqdhaqaaqa dadka, Blackwell
- Myrskylä, Kohler iyo Billari (2009), Addaab ku saabsan horumarinta hoos u dhaca uurka ka dib, Nature 460
- Luci-Greulich iyo Thévenon (2014), Ma horumarka dhaqaalaha ‘caawasho’ dib u kordhinta dhalmada?, * European Journal of Population * 30
- Harttgen iyo Vollmer (2014), A dib u eegis ku saabsan xiriirka horumarka aadanaha la dhalmada?, Dheegashada 51
- Dib u eegis Teknolojiyada MIT (2015), 2015 in biomedicine
- Faahfaahinta deeqda ka Komishanka gargaarka ee diiwaangelinta England iyo Wales iyo xaaladda aan faa’iido doonka ahayn ee Mareykanka ka ProPublica Nonprofit Explorer